Adam Feuerstein

A conversation between @adamfeuerstein and @matthewherper about what Donald Trump's reelection could mean for biotech.

A conversation between @adamfeuerstein and @matthewherper about what Donald Trump's reelection could mean for biotech.

Early data from Arcellx and Gilead Sciences suggest their CAR-T therapy for multiple myeloma could offer a safety advantage over the treatment already on the market.

A patient with #sicklecell disease died while participating in a clinical trial of a CRISPR-based treatment from Beam Therapeutics.

A Trump election victory could empower the MAHA movement, which loathes the pharma industry. But it could also bring an upside for drug developers.

Capricor Therapeutics’ plan to seek early approval for a stem cell therapy for patients with Duchenne muscular dystrophy is daring, @adamfeuerstein writes.

Elon Musk took U.S. drug regulators to task — and got it wrong, @adamfeuerstein writes.

Data in a newly released study on Sarepta Therapeutics Duchenne therapy diverge from the company line, @adamfeuerstein writes.

The next referendum on Gilead Sciences’ oft-criticized oncology business is approaching.

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.